Loading...
Loading...
LBPH| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | -0.0M |
| Operating Expense | 12.0M |
| Operating I/L | -12.0M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.5M |
| Pretax | -11.5M |
| Income Tax Expense | -0.5M |
| Net Income/Loss | -10.9M |
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in transformative medicines for neurological diseases. Its lead product candidate, LP352, is in a Phase 1b/2a clinical trial for treating seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidates, LP659 and LP143, aim to develop therapies for various neurological diseases.
